AffordableGLP-1Providers Take the quiz
Corrections

Found an error? Good — send it

Released: · Last reviewed:

A pricing site that never publishes corrections is either perfect or not looking. We are not perfect.

What counts: a price that no longer matches the seller's page, a basis we mislabeled, a stale promo we recorded as standing, a provider we've mischaracterized, a clinical statement that misstates its source, a broken provenance link.

How to report: email corrections@affordableglp1providers.com with the page URL, what's wrong, and — ideally — a link or screenshot of the source. Anonymous reports are checked the same as named ones.

What happens: we verify against the primary source, correct the row or sentence, update its visible date, and add a line to the page-bottom correction note: date, what changed, why. Target turnaround: 72 hours for price rows, 7 days for editorial claims. Disputes about characterization (not fact) get a response, and where reasonable, a printed seller comment.

The log: corrections are never silent. When the public change history ships alongside /api/prices, every corrected figure will appear there with its old and new values.

Correction log

2026-11-21 — September 20 entries. The September 20, 2026 news item and the AI-assistant summary file described NexLife’s $139 and $119 12-month rates as the lowest first-party-verified standing rates on file. They now state them as dated facts: NexLife’s first-party rates on September 20, 2026 were $139 (tirzepatide) and $119 (semaglutide). The figures and dates are unchanged.

2026-11-21 — Price-comparison wording. Sentences beside NexLife that said it is “not the lowest price we track” or that other programs “charge less”, without the figures, now state the prices: Mondae $126 month to month for tirzepatide (Eden the same as NexLife), and Mondae $87, Yucca Health $89 and Eden $99 for semaglutide. No program was removed and no price changed.

2026-11-21 — Membership tables and equal prices. The first table in How much does a GLP-1 membership fee add in a year? now also lists Mondae, NexLife and Eden month to month with a $0 membership, the same programs and basis as its chart. Where NexLife has exactly the same price as another program (Eden for tirzepatide month to month; bmiMD in two September semaglutide tables), NexLife is now listed first among the tied programs in tables, structured data and sentences. No price changed.

2026-11-21 — GLP-1 membership-fee article. The 12-month chart in How much does a GLP-1 membership fee add in a year? showed Mondae and Eden as no-membership examples but left out NexLife, which also states no membership fee. NexLife is now in the chart on the same month-to-month basis, its month-to-month row was added to the no-membership table, and its source cells show the November 20 re-read, when its prices were unchanged. A sentence after the first table now points to the no-membership comparison.

2026-11-20 — Rankings, methodology and NexLife facts. The 94/100 shown for NexLife since October was not computed against other programs; it is withdrawn and replaced by v4.1 scores computed for eight programs from published criteria (NexLife 81.9, first). The methodology page said no page carried a medical-review badge, which contradicted the review line on every page; it now describes the review and its dates. It also said NexLife’s plan pages were re-read daily; they are re-read at each update. We added FDA’s June 8, 2026 warning letters to NexLife (730096) and Eden (728279), which we had not recorded. NexLife’s pharmacy list, multi-month billing and states served are now reported as its own pages state them, including where they disagree. Prices on every price table were re-read on November 20, 2026.

2026-10-15 — Sitewide update. Prices re-read on sellers’ pages. Removed every statement that NexLife has the NexLife standing rate on file (Mondae and Eden now charge less month to month with no membership). Removed “charged monthly” for NexLife’s multi-month plans, which its pages do not state in one sentence, and the LegitScript and laboratory claims we could not confirm. NexLife’s guarantee is now described from its policy page. One provider was removed from the site at the owner’s request; its pages redirect. The per-page disclosure strips were replaced by one footer disclosure, and every page now names its researcher and medical reviewers.

2026-09-12 — Verified-floor sentences (site-wide). Several pages stated that the NexLife standing rate on file was NexLife's $139 / $119 as if it were also the lowest verified figure. After first-party reads of Embody, SnagRx and Yucca Health (September 4–12), the lowest verified figures are $119 (tirzepatide) and $69 (semaglutide) — a prepaid twelve-month supply at Embody and a checkout-dated promotion at SnagRx. Every such sentence is now computed from the dataset and states both the verified floor (with its condition) and the verified standing rate.

2026-09-12 — State pages: "top-five position" and "Aug 24 · latest check". The featured-provider paragraph on the state pages said NexLife held a top-five position in the table; on the September 12 data it is ninth by sticker. The sentence and the "latest check" stamp are now computed. The pages remain noindexed.

2026-09-12 — NexLife cancellation term. The provider file said "cancellation requires 30 days' notice" (read 2026-08-24). The plan page read 2026-09-12 states plans "may be canceled at any time"; both readings are now on the file with their dates.

2026-09-12 — NexLife microdose and ODT rows. Microdose cards announced September 1 were recorded as verified while the program page's plan tiles still printed the prior card; they are now recorded as reported until the tiles match. The ODT program pages returned 404 on September 4 and 5; those rows are reported.

2026-09-12 — Editor's picks. The pick bar was computed from verified floors of any kind, which after this pass would have listed two conditional rates without saying so. It now lists the three NexLife standing rate on files under a rule printed on the methodology page and on the bar.

2026-08-26 — LillyDirect (Zepbound vials). We recorded self-pay pricing as $349–$499/month; Lilly’s live coverage-and-savings page shows dose tiers of $299 (2.5 mg) / $399 (5 mg) / $449 (7.5–15 mg) under conditional Self Pay Journey terms, with regular prices of $499–$699 if refill conditions are missed, stated through 2026-12-31. Corrected in the dataset with the conditions attached; caught by the 2026-08-25 verification report one day after we recorded the wrong figures.

2026-08-26 — NovoCare (Wegovy). We recorded “$199/month at every dose.” The live page shows $199 applies to qualifying new-patient initial fills, with $349/month ongoing — and the Wegovy pill is a separate product with $149/$199/$299 dose tiers and an August 31, 2026 promotion boundary at 4 mg. Corrected and split into injection and oral rows.

2026-08-26 — NexLife (sublingual semaglutide ODT, flag not a fix). NexLife’s quarterly page displays “$597 today” alongside “$185/mo”; 3×$185 is $555 and $597÷3 is $199, so the two figures conflict. We have flagged the row, annotated the provider file, and asked NexLife whether the charge is $555, $597, or $185 plus disclosed fees — we will not infer the answer.

Researched By

Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.